Dr. Sikic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
# MC5500
Palo Alto, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840- Is this information wrong?
Summary
- Dr. Branimir Sikic is an oncologist at Stanford University. He received his medical degree from University of Chicago Pritzker School of Medicine and was in practice 45 years. He is experienced in ovarian neoplasms and adenocarcinoma. He has more than 250 publications and over 10,000 citings.
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1977 - 1979
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1973 - 1975
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1972 - 1975
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1979 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2010
Clinical Trials
- Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Start of enrollment: 2001 Jul 01
- Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma Start of enrollment: 2003 Mar 01
- A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer Start of enrollment: 2004 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.John F Marcelletti, Branimir I Sikic> ;Cancer Chemotherapy and Pharmacology. 2024 Feb 26
- 2 citationsCarboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.Margareta Pernar Kovač, Vanja Tadić, Juran Kralj, George E Duran, Alessia Stefanelli, Darija Stupin Polančec, Sanja Dabelić, Niko Bačić, Maja T Tomicic, Petra Heffeter...> ;Cellular and Molecular Life Sciences. 2023 Sep 17
- 1 citationsA clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast ...John F Marcelletti, Branimir I Sikic> ;Cancer Chemotherapy and Pharmacology. 2023 Nov 1
- Join now to see all
Press Mentions
Anti-CD47 Antibody Trial in Advanced Cancers Shows Treatment Appears Safe, Well-ToleratedMarch 5th, 2019
Grant Support
- Protocol Specific Research SupportNational Cancer Institute2010–2011
- Taxane Resistance In Breast And Ovarian Cancer CellsNational Cancer Institute2007–2011
- Study Of Oblimersen (Genasensetm, G3139) In Advanced MalignanciesNational Center For Research Resources2006
- Treatment Of Advanced Solid MalignanciesNational Center For Research Resources2005
- Study Of Oblimersen In Combination With Gemcitabine In Advanced MalignanciesNational Center For Research Resources2005
- Regulation Of The Human MDR1 GeneNational Cancer Institute2002–2005
- Phase I Study: Weekly Bms-188797 Alone &With CarboplatNational Center For Research Resources2004
- Phase I Study Of Bms-310705 Given Every Three WeeksNational Center For Research Resources2004
- A Phase I Study Of ZD1839 (Iressa Tm) With OxaliplatinNational Center For Research Resources2004
- A Phase I Study Of Oblimersen (Genasense TM, G3139)National Center For Research Resources2004
- Gene Expression Profiling Of Unknown Primary CancersNational Cancer Institute2001–2003
- Modulation Of Multidrug Resistance MechanismsNational Cancer Institute1999–2002
- Phase I Trial Of Oral Paclitaxel And Valspodar (Psc 833)National Center For Research Resources2000–2001
- Phase I Trial Of Doxil, Paclitaxel And Valspodar PSC 833National Center For Research Resources2000–2001
- Ly335979 &Mitoxantrone In Prostate CancerNational Center For Research Resources2000–2001
- Phase I Trial Of Antisense Inhibitor Of Protein Kinase C Alpha In CanNational Center For Research Resources1999–2001
- Phase II Of ISIS 3521 In Patients With Ovarian CarcinomaNational Center For Research Resources1998–2001
- Phase I Protein Kinase, Carboplatin And Paclitaxel Chemo. For CancerNational Center For Research Resources1998–2001
- Paclitaxel And PSC 833 In Metastatic Colorectal CarcinomaNational Center For Research Resources1998–2001
- Phase I Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources1997–2001
- CGP 64128a Administered As A Continuous Infusion In Patients With CancerNational Center For Research Resources1998–1999
- Tubulin Genes And Drug ResistanceNational Cancer Institute1996–1998
- Expression And Modulation Of Multidrug ResistanceNational Cancer Institute1990–1998
- Phase II Clinical Trial Of Paclitaxel &Psc 833 In Metastatic Colorectal CancerNational Center For Research Resources1997
- Phase I Clinical Trial Of Cgp64128a Administered As A Continuous InfusionNational Center For Research Resources1997
- Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources1996
- Phase 1 Trial Of Taxol And PSC-833 ChemotherapyNational Center For Research Resources1996
- Cyano-Morpholino AnthracyclinesNational Cancer Institute1986–1988
Professional Memberships
- Member
- Fellow
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
